New York City Event to Spotlight MASLD and MASH, Diabetes, and Metabolic Health. @AASLDtweets @EASLedu @CanMASLDNetwork @AmDiabetesAssn @WorldObesity @MadrigalPharma @novonordisk @Regeneron @Echosens @echosensNA #livertwitter #liverx https://t.co/IWE5w9GTkJ

We are excited to announce our next Your Liver Your Health event with Dr. @MeenaBBansal in NYC on September 24, 2025. We would love to have you there too! We will be offering FREE liver health assessments (thank you Echosens), we will have the very famous realistic liver model

30-Day Glucose Challenge: Halfway Update. For me, feedback with my digital tools makes all the difference in the world! Keep following for the next 2 weeks. 96% of my glucose readings are in range. 1. Down 7.4 lbs of fat (26.7% to 22.4% and 40.3 lbs to 32.9 lbs) 2. Up 4.9 lbs

Watch this powerful 2-minute moment from our Your Liver, Your Health event in Chicago. Dr. @marurinella and her patient, Kerry Sivia, share something rare, a bond built on mutual trust, respect, and advocacy. In this candid conversation with @betelm, President of the Fatty

The Fatty Liver Alliance invites you to take part in our 3rd Annual 30 Day Glucose Challenge, starting July 1! This challenge is a powerful opportunity to raise awareness and take action around Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic

We renamed a disease—not for science, but for people. 🩺 Proud to co-author the People-First Liver Charter alongside greats in @NaturePortfolio 🔗 https://t.co/Z6KWYy4k5P Words can heal. Let’s end stigma in MASLD/MASH—across every specialty. 🌍💬

Resmetirom was approved for MASH 14 months ago in the US and is likely to gain approval in the EU shortly, with semaglutide close behind. 🩺 Experts are discussing how these approvals changed their clinical practice, and how the first approval opens the gates and clarifies the

And we are thrilled to see the coverage of steatotic liver disease today in the @guardian! https://t.co/Ua1a27ICew @AlkhouriNaim @schattenbergJ @DidacMauricio @LuisAntonioDiaz @scottisaacsmd @brennap9 #SLDthinktank #LiverTwitter

Today on Clinical Trials Day, we’re celebrating the incredible impact of clinical research professionals like you. Your dedication is what drives medical progress forward — from the earliest stages of discovery to tomorrow’s breakthrough treatments. Every protocol you design,

At American Association of Clinical Endocrinology (@TheAACE) #aace2025 conference, Dr. @scottisaacsmd, FACP, FACE delivered a powerful call-to-action for Endocrinologists to take ownership of diagnosing and managing Metabolic dysfunction-Associated Steatotic Liver Disease

Dr. Kenneth Cusi one of the world’s foremost endocrinologists in metabolic liver disease, delivered a powerful reminder: endocrinologists are on the front lines of MASLD (formerly NAFLD) and MASH care—whether they realize it or not. Key Takeaways: •Type 2 diabetes & obesity are

At #AACE2025, Professor @JVLazarus delivered a comprehensive overview of the evolving landscape of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD and MASH), emphasizing why this matters now more than ever for endocrinologists and the broader medical community.

Congratulations Professor @JVLazarus! Sherri and I (@betelm) are proud to be here at #AACE2025 with you and Julie and your parents to celebrate the incredible achievement of receiving the Eugene T. Davidson, MD, Public Service Award. This is a well-deserved recognition for your